The APOE ε 2 allele increases the risk of earlier age at onset in Machado-Joseph disease

Archives of Neurology

Volumn 68, Issue 12, 2011, Pages 1580-1583

  Bettencourt, Conceição ^a,c,e   Raposo, Mafalda ^c   Kazachkova, Nadiya ^a,c   Cymbron, Teresa ^a,c   Santos, Cristina ^f   Kay, Teresa ^g   Vasconcelos, João ^d   Maciel, Patrícia ^h   Donis, Karina C ^j   Saraiva Pereira, Maria Luiza ^i,j   Jardim, Laura B ^i,j   Sequeiros, Jorge ^a,b   Lima, Manuela ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF THE AZORES   (Portugal)

^d HOSPITAL DO DIVINO ESPÍRITO SANTO   (Portugal)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^g HOSPITAL DONA ESTEFÂNIA   (Portugal)

^h UNIVERSITY OF MINHO   (Portugal)

ⁱ FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^j HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GUANINE;

ADOLESCENT; ADULT; AGED; ALLELE; APOLIPOPROTEIN E EPSILON2 GENE; ARTICLE; BLOOD SAMPLING; BRAZIL; CASE STUDY; CHILD; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENETIC RISK; GENOTYPE; HIGH RISK POPULATION; HUMAN; MACHADO JOSEPH DISEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PORTUGAL; PREDICTION; PRIORITY JOURNAL;

EID: 83455217478     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.636     Document Type: Article

References (48)

1. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8(3):221-228. (Pubitemid 24338732)
2. Ichikawa Y, Goto J, Hattori M, et al. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet. 2001;46(7):413-422. (Pubitemid 32634516)
3. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004;3(5):291-304. (Pubitemid 38510200)
4. Bettencourt C, Santos C, Kay T, Vasconcelos J, Lima M. Analysis of segregation patterns in Machado-Joseph disease pedigrees. J Hum Genet. 2008;53(10):920-923.
5. Maciel P, Costa MC, Ferro A, et al. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol. 2001;58(11):1821-1827. (Pubitemid 33044249)
6. van Alfen N, Sinke RJ, Zwarts MJ, et al. Intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol. 2001;49(6):805-807.
7. Carvalho DR, La Rocque-Ferreira A, Rizzo IM, Imamura EU, Speck-Martins CE. Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr Neurol. 2008;38(4):296-299. (Pubitemid 351382134)
8. Coutinho P. Doenc?a de Machado-Joseph: Tentativa de definiçã o [dissertation]. Porto, Portugual: Instituto de Cie?ncias Biome?dicas Abel Salazar; 1992.
9. Maciel P, Gaspar C, DeStefano AL, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet. 1995;57 (1):54-61.
10. Maruyama H, Nakamura S, Matsuyama Z, et al. Molecular features of the CAG repeats and clinical manifestation of Machado-Joseph disease. Hum Mol Genet. 1995;4(5):807-812.
11. DeStefano AL, Cupples LA, Maciel P, et al. A familial factor independent of CAG repeat length influences age at onset of Machado-Joseph disease. Am J Hum Genet. 1996;59(1):119-127. (Pubitemid 26189736)
12. van de Warrenburg BP, Hendriks H, Dürr A, et al. Age at onset variance analysis in spinocerebellar ataxias: a study in a Dutch-French cohort. Ann Neurol. 2005;57(4):505-512. (Pubitemid 40471159)
13. Hayes S, Turecki G, Brisebois K, et al. CAG repeat length in RAI1 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2). Hum Mol Genet. 2000;9(12):1753-1758. (Pubitemid 30608609)
14. Jardim L, Silveira I, Pereira ML, et al. Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype. Acta Neurol Scand. 2003;107(3):211-214. (Pubitemid 36398997)
15. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622-630.
16. Lin-Lee YC, Kao FT, Cheung P, Chan L. Apolipoprotein E gene mapping and expression: localization of the structural gene to human chromosome 19 and expression of ApoE mRNA in lipoprotein- and non-lipoprotein-producing tissues. Biochemistry. 1985;24(14):3751-3756. (Pubitemid 15011913)
17. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981;256(17):9077-9083. (Pubitemid 12208303)
18. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci. 2006;31(8):445-454. (Pubitemid 44108662)
19. Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721-1731. (Pubitemid 41099339)
20. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system: characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem. 1987;262(29):14352-14360. (Pubitemid 17152101)
21. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem. 2008;49:241-268.
22. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333-344.
23. Schipper HM. Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment [published online May 29, 2009]. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.04.021.
24. Sando SB, Melquist S, Cannon A, et al. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol. 2008;8:9. doi:10.1186/1471-2377-8-9.
25. Caselli RJ. Age-related memory decline and apolipoprotein E e4. Discov Med. 2009;8(41):47-50.
26. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology. 2004;63(10):1898-1901. (Pubitemid 39532387)
27. Teasdale GM, Nicoll JA, Murray G, FiddesM. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997;350(9084):1069-1071. (Pubitemid 27437858)
28. Crawford FC, Vanderploeg RD, Freeman MJ, et al. APOE genotype influences acquisition and recall following traumatic brain injury. Neurology. 2002;58(7): 1115-1118. (Pubitemid 34298559)
29. Huang X, Chen PC, Poole C. APOE-ε2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004;62(12):2198-2202. (Pubitemid 38787775)
30. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord. 2000; 15(4):714-719. (Pubitemid 30479626)
31. Zareparsi S, Camicioli R, Sexton G, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet. 2002;107(2):156-161. (Pubitemid 34038598)
32. Verpillat P, Camuzat A, Hannequin D, et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet. 2002;10(7):399-405.
33. Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999;36(2):108-111. (Pubitemid 29101384)
34. Bettencourt C, Fialho RN, Santos C, et al. Segregation distortion of wild-type alleles at the Machado-Joseph disease locus: a study in normal families from the Azores islands (Portugal). J Hum Genet. 2008;53(4):333-339.
35. Bettencourt C, Montiel R, Santos C, et al. Polymorphism of the APOE locus in the Azores Islands (Portugal). Hum Biol. 2006;78(4):509-512. (Pubitemid 46106357)
36. Seixas S, Trovoada MJ, Rocha J. Haplotype analysis of the apolipoprotein E and apolipoprotein C1 loci in Portugal and São Tomé e Príncipe (Gulf of Guinea): linkage disequilibrium evidence that APOE*4 is the ancestral APOE allele. Hum Biol. 1999;71(6):1001-1008.
37. Schiele F, De Bacquer D, Vincent-Viry M, et al. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis. 2000;152(2):475-488.
38. de-Andrade FM, Larrandaburu M, Callegari-Jacques SM, Gastaldo G, Hutz MH. Association of apolipoprotein E polymorphism with plasma lipids and Alzheimer's disease in a Southern Brazilian population. Braz J Med Biol Res. 2000; 33(5):529-537.
39. Souza DR, Campos BF, Arruda EF, Yamamoto LJ, Trindade DM, Tognola WA. Influence of the polymorphism of apolipoprotein E in cerebral vascular disease. Arq Neuropsiquiatr. 2003;61(1):7-13. (Pubitemid 36396152)
40. Schneider S, Roessli D, Excoffier L. Arlequin: A Software for Population Genetics Data Analysis, Version 2.000. Geneva, Switzerland: Genetics and Biometry Laboratory, Department of Anthropology, University of Geneva; 2000.
41. SPSS for Windows [computer program]. Release 15.0. Chicago, IL: SPSS Inc; 2006.
42. Baird PN, Richardson AJ, Robman LD, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). HumMutat. 2006;27(4):337-342.
43. Tikellis G, Sun C, Gorin MB, et al. Apolipoprotein E gene and age-related maculopathy in older individuals: the Cardiovascular Health Study. Arch Ophthalmol. 2007;125(1):68-73. (Pubitemid 46072378)
44. Tuite PJ, Rogaeva EA, St George-Hyslop PH, Lang AE. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol. 1995;38(4):684-687.
45. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol. 2001;58(2):296-299. (Pubitemid 32163168)
46. Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord. 2003;18(2):219-221. (Pubitemid 36305470)
47. Saft C, Andrich JE, Brune N, et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J Neurol Neurosurg Psychiatry. 2004;75(12):1692-1696. (Pubitemid 39611467)
48. Rapp A, Gmeiner B, Hu?ttinger M. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie. 2006;88(5):473-483. (Pubitemid 43867898)